The Research & Development team invites you to attend a lecture by Olivera Finn, PhD, Distinguished Professor and Director of Immunology Program, University of Pittsburgh, Pennsylvania.

Dr. Finn’s research is focused on designing effective cancer immunotherapy, primarily vaccines for breast, pancreatic, colon and lung cancers. Dr. Finn’s laboratory was one of the first to study human T cell responses against these tumors and, in 1989, the first to identify an abnormal form of the human mucin MUC1 as a tumor antigen and a target of cytotoxic T cells. This work led to the identification of a unique peptide epitope on MUC1 molecule culminating in the approval of an investigational new drug by the FDA, which has been tested as a vaccine for pancreatic, prostate, colon and lung cancer. Most recently, MUC1 peptide vaccine is being tested in premalignant setting as a prophylactic vaccine in patients with a history of advanced adenomas in order to prevent their progression to colon cancer.

**Presentation Title:** MUC1 vaccines for cancer prevention and a lot more  
**Date/Time:** Friday, January 12, 12 - 1 pm  
**Location:** Auditorium 5104 ABCD  
**Presenter:** Olivera Finn, PhD

Box lunch will be offered to the first 40 people at 11:45 am. Please come early to secure a seat.